Price
No data yet.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-10.31M | $-2.39 |
| 2024 | $0.00 | $-7.52M | $-8.08 |
| 2023 | $0.00 | $-6.91M | $-30.05 |
| 2022 | $0.00 | $-17.87M | $-11.08 |
| 2021 | $0.00 | $-32.47M | $-19.48 |
Social Signal Score
Earnings
Mon, Aug 17(date passed)
Consensus estimate $-0.39 per share
Typical surprise +23.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 8$-0.29 vs $-0.38beat
- Tue, Mar 31$-0.92 vs $-0.51miss
- Wed, Nov 26$-0.33 vs $-0.54beat
- Thu, Aug 28$-0.63 vs $-0.83beat
- Thu, May 22$-0.62 vs $-0.89beat
- Wed, Apr 2$-1.94 vs $-0.89miss
Estimates and results for GLMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
GLMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsprnewswire.com·5h ago·Neutral
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global sales for Xtandi® (marketed
View source ↗